Ind-Swift enters into an agreement with Roche Diagnostics India

16 Jan 2012 Evaluate

Ind-Swift, a Chandigarh based pharmaceutical company has entered into an agreement with Roche Diagnostics India to promote test for detecting heart attack, TROP T rapid assay, in India. Roche Diagnostics' TROP T rapid assay is a point of care test which can detect whether a patient is having a heart attack through a simple whole blood test.

Troponin - T is used to measure damage to the heart muscle and to differentiate between non-cardiac chest pains and heart attacks. The TROP T rapid assay gives a reliable qualitative result within 15 minutes.

Ind-Swift has a cardio specific field force, CARDIASWIFT which has been marketing cardio & anti-diabetic products for the last 8-10 years. Ind-Swift will promote TROP T to cardiologists / diabectologists / consulting physicians/general practitioners all over the country with its 225 strong field force.

Roche Diagnostics India is part of Roche Group, a worldwide leader in the field of Medical Diagnostics and Pharmaceuticals.

Ind-Swift manufactures and markets finished dosage forms, through its different divisions, focusing on the needs of various therapeutic segments. The divisions include Super Speciality, Animal Division, Daignozis, Institutions, Agile, Bio Sciences, Ethical, Health Care, Max Care, Mega care, Neuro and Resurgence.

Ind-Swift - Amalgama Share Price

15.70 0.00 (0.00%)
13-Aug-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×